Department of Radiology, Eberhard-Karls University Tuebingen, Tuebingen, Germany.
Radiology. 2012 Aug;264(2):551-8. doi: 10.1148/radiol.12111942. Epub 2012 May 31.
To compare the performance of magnetic resonance (MR)/positron emission tomography (PET) imaging in the staging of lung cancer with that of PET/computed tomography (CT) as the reference standard and to compare the quantification accuracy of a new whole-body MR/PET system with corresponding PET/CT data sets.
Institutional review board approval and informed consent were obtained. Ten patients in whom bronchial carcinoma was proven or clinically suspected underwent clinically indicated fluorine 18 fluorodeoxyglucose (FDG) PET/CT and, immediately thereafter, whole-body MR/PET imaging with a new hybrid whole-body system (3.0-T MR imager with integrated PET system). Attenuation correction of MR/PET images was segmentation based with fat-water separation. Tumor-to-liver ratios were calculated and compared between PET/CT and MR/PET imaging. Tumor staging on the basis of the PET/CT and MR/PET studies was performed by two readers. Spearman rank correlation was used for comparison of data.
MR/PET imaging provided diagnostic image quality in all patients, with good tumor delineation. Most lesions (nine of 10) showed pronounced FDG uptake. One lesion was morphologically suspicious for malignancy at CT and MR imaging but showed no FDG uptake. MR/PET imaging had higher mean tumor-to-liver ratios than did PET/CT (4.4 ± 2.0 [standard deviation] for PET/CT vs 8.0 ± 3.9 for MR/PET imaging). Significant correlation regarding the tumor-to-liver ratio was found between both imaging units (ρ = 0.93; P < .001). Identical TNM scores based on MR/PET and PET/CT data were found in seven of 10 patients. Differences in T and/or N staging occurred mainly owing to modality-inherent differences in lesion size measurement.
MR/PET imaging of the lung is feasible and provides diagnostic image quality in the assessment of pulmonary masses. Similar lesion characterization and tumor stage were found in comparing PET/CT and MR/PET images in most patients.
比较磁共振（MR）/正电子发射断层扫描（PET）成像在肺癌分期中的表现与 PET/计算机断层扫描（CT）作为参考标准的表现，并比较新型全身 MR/PET 系统与相应的 PET/CT 数据集的定量准确性。
本研究获得了机构审查委员会的批准和患者的知情同意。10 例经支气管癌证实或临床怀疑患有支气管癌的患者接受了临床推荐的氟 18 氟脱氧葡萄糖（FDG）PET/CT 检查，随后立即使用新型全身混合系统（3.0-T MR 成像仪与集成 PET 系统）进行全身 MR/PET 成像。MR/PET 图像的衰减校正采用基于分割的油水分离法。计算并比较了 PET/CT 和 MR/PET 成像之间的肿瘤与肝脏比值。两名读者根据 PET/CT 和 MR/PET 研究进行肿瘤分期。采用 Spearman 秩相关进行数据比较。
MR/PET 成像在所有患者中均提供了诊断性图像质量，具有良好的肿瘤描绘。大多数病变（10 例中有 9 例）显示出明显的 FDG 摄取。1 个病变在 CT 和 MR 成像上形态学上怀疑为恶性，但无 FDG 摄取。MR/PET 成像的肿瘤与肝脏比值高于 PET/CT（PET/CT 为 4.4±2.0[标准差]，MR/PET 成像为 8.0±3.9）。两种成像设备之间的肿瘤与肝脏比值存在显著相关性（ρ=0.93；P<.001）。10 例患者中有 7 例基于 MR/PET 和 PET/CT 数据的 TNM 评分相同。T 和/或 N 分期的差异主要归因于病变大小测量的固有模态差异。
肺部 MR/PET 成像可行，可提供肺部肿块评估的诊断图像质量。在大多数患者中，比较 PET/CT 和 MR/PET 图像发现，病变特征和肿瘤分期相似。
